These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12811113)

  • 1. Drugs, health and the economy: investment, innovation, outcomes, growth.
    Montague T; Cavanaugh S; Skilton K; Szabo G; Sidel J; Gregoire JP
    Healthc Pap; 2002; 3(1):63-9; discussion 87-94. PubMed ID: 12811113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing healthcare costs within an integrated framework.
    Fernandes R
    Healthc Pap; 2002; 3(1):70-6; discussion 87-94. PubMed ID: 12811114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More of the same is not enough.
    Willison DJ
    Healthc Pap; 2002; 3(1):47-55; discussion 87-94. PubMed ID: 12811111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health, healthcare and nation-building: a three-dimensional approach to innovation in Canada.
    Brimacombe GG
    Healthc Q; 2005; 8(3):61-5, 2. PubMed ID: 16078404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug policy: the challenge is to overcome fragmentation.
    McFarlance A
    Healthc Pap; 2002; 3(1):38-42: discussion 87-94. PubMed ID: 12811109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to medical care under strain: new pressures in Canada and Australia.
    Gray G
    J Health Polit Policy Law; 1998 Dec; 23(6):905-47. PubMed ID: 9866093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Look beyond budgets to the broader benefits.
    Dugal R; Mani A; Potvin K
    Healthc Pap; 2002; 3(1):77-82; discussion 87-94. PubMed ID: 12811115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare: innovation is the key to sustainability?
    Rachlis MM
    Healthc Manage Forum; 2005; 18(1):28-31. PubMed ID: 15913227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Let evidence be the arbiter.
    Lindberg MC
    Healthc Pap; 2002; 3(1):43-6; discussion 87-94. PubMed ID: 12811110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable.
    Levy AR; Gagnon YM
    Healthc Pap; 2002; 3(1):32-7; discussion 87-94. PubMed ID: 12811108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
    Antoñanzas F
    Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
    Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
    Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug spending in Canada: recent trends and causes.
    Morgan S
    Med Care; 2004 Jul; 42(7):635-42. PubMed ID: 15213487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS).
    Crémieux PY; Fortin P; Meilleur MC; Montague T; Royer J
    Healthc Q; 2007; 10(2):38-46. PubMed ID: 17491566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A national drug agency.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    CMAJ; 2003 Apr; 168(8):962-3. PubMed ID: 12695372
    [No Abstract]   [Full Text] [Related]  

  • 19. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
    Hsieh CR; Sloan FA
    Value Health; 2008; 11(2):334-44. PubMed ID: 18380646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. We need Romanow's National Drug Agency.
    CMAJ; 2003 Feb; 168(3):249, 251. PubMed ID: 12566321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.